2-Ethyl-6-methyl-1-benzothiophene

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 2-Ethyl-6-methyl-1-benzothiophene
• 英文别名: 2-ethyl-6-methyl-1-benzothiophene
• 化学式: C₁₁H₁₂S
• 分子量: 176.28
• InChiKey: IPGWYOVQLXQTPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• ANTIVIRAL COMPOUNDS
  申请人：Bacon Elizabeth M.

  公开号：US20140249074A1

  公开（公告）日：2014-09-04

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  本发明涉及抗病毒化合物、含有该类化合物的组合物、包括给予该类化合物的治疗方法，以及用于制备该类化合物的过程和中间体。
• OXAZOLIDONE COMPOUND, PREPARING METHOD AND APPLICATION THEREOF
  申请人：SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

  公开号：US20150361091A1

  公开（公告）日：2015-12-17

  The present invention relates to the field of a pharmaceutical compound, and more specifically, relates to a new oxazolidone compound, an enantiomer, a diastereoisomer and a raceme thereof, and a mixture thereof, and a pharmaceutically acceptable salt thereof, a preparation method thereof, an application thereof as a bioactive substance in a drug. The compound in the present invention has strong anticoagulant activity, does not affect the activity of thrombin, and can reduce the risk of hemorrhage. A pharmacokinetics experiment shows that the compound in the present invention further has good metabolic characteristics, and has a far better oral bioavailability than a positive contrastive agent rivaroxaban.

  本发明涉及制药化合物领域，更具体地涉及一种新的噁唑烷化合物，其对映异构体、二对映异构体和混合物，以及其药学上可接受的盐、制备方法及其在药物中作为生物活性物质的应用。本发明中的化合物具有强烈的抗凝血活性，不影响凝血酶的活性，并能降低出血风险。药代动力学实验表明，本发明中的化合物还具有良好的代谢特性，并且具有比阳性对照剂利伐沙班更好的口服生物利用度。
• RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF
  申请人：Beijing Tide Pharmaceutical Co., Ltd.

  公开号：EP3647311A1

  公开（公告）日：2020-05-06

  The present invention relates to a Rho-associated protein kinase inhibitor of formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and a use of the same in preventing or treating a disease mediated by Rho-associated protein kinase (ROCK).

  本发明涉及一种式（I）的Rho相关蛋白激酶抑制剂、一种包含其的药物组合物、其制备方法以及其在预防或治疗由Rho相关蛋白激酶（ROCK）介导的疾病中的用途。
• Benzothienothiophene isoindigo polymers
  申请人：BASF SE

  公开号：US10669371B2

  公开（公告）日：2020-06-02

  Polymers comprising at least one unit of formula (1) and their use as semiconducting materials.

  包含至少一个式（1）单元的聚合物及其作为半导体材料的用途。
• US8822430B2
  申请人：——

  公开号：US8822430B2

  公开（公告）日：2014-09-02